Skip to main content

Table 1 Baseline characteristics of HIV patients receiving IL-6 inhibition for COVID-19 pneumonia

From: Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series

Pt

Sex

Age

Race/ethnicity

Location

Most recent VL

CD4

ART

Comorbid conditions

1

F

60

White, non-Hispanic

Int

Undetectable

600

2 NRTIs + PI + INSTI

COPD, CKD, Cirrhosis

2

M

39

Hispanic, white

Int

Undetectable

354

2 NRTIs + INSTI

HTN

3

M

74

Black, non-Hispanic

MA

Undetectable

238

2 NRTIs + INSTI

HTN, CKD, malignancy

4

F

76

Black, non-Hispanic

PA

Undetectable

205

2 NRTIs + INSTI

HTN, DM, Asthma, CKD

5

M

61

White, non-Hispanic

NY

29

62

2 NRTIs + INSTI + CYP3Ai + PI

Asthma

6

M

60

Hispanic; non-white

NY

Undetectable

1200

2 NRTIs + INSTI

None

7

M

59

Hispanic; non-white

NY

Undetectable

298

NNRTI + INSTI

HTN, DM

8

F

68

Hispanic, non-white

NY

Undetectable

186

2 NRTIs + INSTI

Cirrhosis

9

M

80

Black. non-Hispanic

NY

Undetectable

296

2 NRTIs + NNRTI

HTN, CKD

10

F

39

White, non-Hispanic

NY

Unknown

85

2 NRTIs + INSTI

None

11

M

29

Hispanic, non-white

NY

Undetectable

465

2 NRTIs + INSTI

HTN

12

M

36

Hispanic, white

TX

24

328

2 NRTIs + NNRTI

None

13

M

70

White, non-Hispanic

TX

Undetectable

260

2 NRTIs + INSTI

COPD, CKD

14

F

57

Black, non-Hispanic

PA

84

250

2 NRTIs + INSTI

HTN, DM, CKD

15

M

81

Hispanic, non-white

TX

91

345

2 NRTIs + PI

DM, malignancy

16

M

70

White, non-Hispanic

TX

Undetectable

260

2 NRTIs + NNRTI

COPD

17

M

61

Hispanic, non-white

NY

Undetectable

NR

2 NRTIs + INSTI

HTN, CAD

18

M

57

Black, non-Hispanic

MD

326

111

N/A

None

  1. Pt patient, Int international, MA Massachusetts, PA Pennsylvania, NY New York, TX Texas, MD Maryland, VL viral load (1000 copies/mL), CD4 most recent documented absolute CD4 count (cells/mm [3]), COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, HTN hypertension, DM diabetes mellitus, ART antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRT non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, INSTI integrase strand transfer inhibitor, CYP3Ai CYP3A inhibitor, N/a new diagnosis not on treatment